Literature DB >> 6488493

Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization.

W J Stewart, S M McSweeney, M A Kellett, D P Faxon, T J Ryan.   

Abstract

Protamine is widely used for reversing systemic heparinization after cardiac catheterization. Although rare, major reactions to protamine that simulate anaphylaxis occasionally occur and have previously been associated only with an allergic reaction to fish. Because neutral protamine Hagedorn (NPH) insulin includes protamine, it might be anticipated that NPH insulin-dependent diabetic patients would develop sensitivity to protamine. Of 866 consecutive patients undergoing cardiac catheterization over a 20 month period, 651 received protamine for reversal of heparinization. Of these, 8.5% (56/651) were diabetics and 2.3% (15/651) were NPH insulin-dependent diabetics. During this period seven patients were observed immediately after administration of protamine to have major adverse reactions that required the administration of catecholamines. One death ensued. Of the seven major reactions, four occurred in NPH insulin-dependent diabetics and one occurred in a patient with an allergy to fish. The incidence of major protamine reactions was 27% (4/15) in the NPH insulin-dependent diabetics vs 0.5% (3/636) in those with no history of NPH insulin use (p less than .001). This represents a 50-fold increased risk of a major reaction to protamine if the patient was receiving NPH insulin. Accordingly, we recommend that diabetics on NPH insulin and patients with allergies to fish undergo cardiac catheterization without the use of protamine or, when necessary, that protamine be administered cautiously in anticipation of a major adverse reaction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488493     DOI: 10.1161/01.cir.70.5.788

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Case files of the Harvard Medical Toxicology Fellowship at Children's Hospital Boston: an insulin overdose.

Authors:  Aaron Benjamin Skolnik; Michele Burns Ewald
Journal:  J Med Toxicol       Date:  2010-12

2.  Methylene Blue to Treat Protamine-induced Anaphylaxis Reactions. An Experimental Study in Pigs.

Authors:  Agnes Afrodite S Albuquerque; Edson A Margarido; Antonio Carlos Menardi; Adilson Scorzoni; Andrea Carla Celotto; Alfredo J Rodrigues; Walter Vilella A Vicente; Paulo Roberto B Evora
Journal:  Braz J Cardiovasc Surg       Date:  2016 May-Jun

Review 3.  Insulin allergy.

Authors:  L Grammer
Journal:  Clin Rev Allergy       Date:  1986-05

4.  Marked systemic hypotension accompanied by pulmonary hypertension following protamine reversal of heparin: Case report.

Authors:  Takashi Horiguchi; Keiji Enzan; Junichi Matsumoto; Mamoru Kadosaki; Masahiro Suzuki
Journal:  J Anesth       Date:  1994-12       Impact factor: 2.078

5.  Protamine and protamine-insulins exacerbate the vascular response to injury.

Authors:  E R Edelman; L A Pukac; M J Karnovsky
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

Review 7.  Allergy to protamine.

Authors:  M E Weiss; N F Adkinson
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

Review 8.  Antiplatelet medications and evolving antithrombotic medication.

Authors:  Jonathan Ryan; Ferdia Bolster; Ian Crosbie; Eoin Kavanagh
Journal:  Skeletal Radiol       Date:  2013-01-19       Impact factor: 2.199

Review 9.  Allergic reactions to fish.

Authors:  C O'Neil; A A Helbling; S B Lehrer
Journal:  Clin Rev Allergy       Date:  1993

10.  Periprocedural management of anticoagulation and antiplatelet therapies in patients undergoing electrophysiologic procedures.

Authors:  Jordana Kron; Daniel Alexander; Mark A Wood
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.